NCT01863147

Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Wuhan General Hospital of Guangzhou Military Command · Academic / Other
• Sex: All
• Age: 55 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Cardiovascular complications account for the highest mortality in type 2 diabetic patients, mainly due to coronary artery disease (CAD).Left ventricular hypertrophy (LVH) is widespread in type 2 diabetic patients with CAD, even in the absence of hypertension .It is a strong predictor of cardiovascular events and all-cause mortality . Sitagliptin, an inhibitor of dipeptidyl peptidase-4 (DPP-4), may regress left ventricular mass (LVM) in newly diagnosed type 2 diabetic patients with CAD .

Conditions

• Newly Diagnosed Type 2 Diabetes
• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Sitagliptin and acarbose	Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.

Timeline

• Start date: 2013-07-01
• Primary completion: 2015-07-01
• Completion: 2015-07-01
• First posted: 2013-05-27
• Last updated: 2015-08-18

Locations

2 sites across 1 country: China